| |
 |
This is the category page. Below are all of the research programs that are associated with it
- Fleu Vaccine:
SAFETY AND IMMUNOGENICITY OF REVACCINATION WITH INFLUENZA VACCINE IN HEALTHY ADULT SUBJECTS AGED 18 TO 64 YEARS WHO WERE PREVIOUSLY VACCINATED WITH FLUZONE ID OR FLUZONE IM” (Trial FID33, Version 2.0 dated June 11, 2009; consent version 1.0 dated July 20, 2009)
(1_20090714_118)
This study is for participants who were previously vaccinated with Fluzone ID or Fluzone IM. There are four arms to this study. Participants will now be randomized to one of the four arms based on the vaccine route during the last trial they participated in. All participants will receive follow-up telephone calls to review potential problems or medical events of special interest about 8 days after the vaccination. Blood test will be done right before the vaccination; and the second one will be on day 28 following the vaccination. All participants will receive a 6 month follow-up phone call. Participants will need to complete diary cards.
- Flu Vaccine -
LOT CONSISTENCY, IMMUNOGENICITY, AND SAFETY STUDY OF THREE LOTS OF FLUZONE VACCINE ADMINISTERED BY INTRADERMAL ROUTE IN COMPARISON WITH STANDARD FLUZON® ADMINISTERED INTRAMUSCULARLY IN ADULT SUBJECTS AGED 18 TO 64 YEARS (#FID31)
(1_20080809_118)
This is a phase III, multicenter, randomized, active-controlled study. Participants will give a baseline blood sample and then be randomized to receive on of three different lots of Fluzone ID or Fluzone IM. Participants will then be monitored for side effects of the vaccination such as pain, redness, swelling, etc. Participants will receive a follow-up phone call on Day 8 following vaccination to assess for any problems. All participants will return for repeat blood testing on Day 28 to assess antibody to the vaccine. Participants will then be seen at 6 months to monitor for the development of new medical conditions.
- Skin Infections -
A RANDOMIZED, EVALUATOR-BLINDED, PHASE 3 STUDY TO COMPARE THE SAFETY AND EFFICACY OF PTK 0796 WITH LINEZOLID IN THE TREATMENT OF ADULTS WITH COMPLICATED SKIN AND SKIN STRUCTURE INFECTION (Protocol PTK 0796-CSSI-0804)
(1_20090204_118)
This is a randomized, evaluator – blinded , Phase III study to compare a new antibiotic treatment (PTK 0796) to linezolid for the treatment of complicated skin and skin structure infections. Participants will be randomized to one of the two treatment groups and receive intravenous dosing for four to seven days with a switch to oral dosing when appropriate. Total treatment duration is 14 days. Follow up will be 32 days from the initial dose of study medication.
- Study Closed to Accrual: Clostridium Difficile -
A DOUBLE-BLIND, RANDOMIZED, CONTROLLED TRIAL OF RIFAXIMIN COMPARED TO VANCOMYCIN FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA (CDAD) (PROTOCOL #RFCL3001) (2_20051207_118)
This is a phase 3, double-blind, randomized, active comparator-controlled study in subjects with primary Clostridium Difficile-associated diarrhea. The study includes a screening phase, treatment phase, test of cure, and follow-up contact.
|
|
